Aspen Pharmacare Holdings Ltd. has received two unsolicited offers for its active pharmaceutical ingredient business and will start a process aimed at evaluating proposals for the unit.
The approaches are for operations almost exclusively in Europe and make both chemicals and the anticoagulant drug heparin, Chief Executive Officer Stephen Saad said by phone Thursday. The company has has already sold most of its other heparin interests, part of a recent slimming down effort to reduce debt.
